Large Molecular Generic Injectable Drugs Market to Expand at a CAGR of 34.8% Through 2025
The market report envelopes an all-in information of the global Generic Injectable market and the nature of the market growth over the foreseeable period. The report provides a comprehensive elaboration of the positives and negatives of the global Generic Injectable market with DROT and Porter’s Five Forces analysis. With SWOT analysis, the report offers detailed insights about different players operating within the Generic Injectable market. In addition, the analysts of the report have served the qualitative and quantitative scrutinizing of different micro- and macro-economic factors influencing the global Generic Injectable market.
For detailed insights on enhancing your product footprint, request for a sample here- https://www.factmr.com/connectus/sample?flag=S&rep_id=4681
In recent years, demand for generic drugs has seen a prolific rise. High developmental and investment costs associated with branded formulations has prompted key players to invest in alternative formulae which are more affordable and accessible to people, especially in the developing world.
On the back of abovementioned factors, the global generic injectables market is projected to witness an impressive growth during the forecast period (2020-2025). Projected CAGR for the global generic injectables market is pegged at 13.3%, to reach a value pool of US$ 1.5 Bn by the end of 2025.
However, significant challenges for growth exist for the global generic injectables market. Supply-chain disruptions occurring due to limited availability of air and water transport is a major restraint. This is anticipated to create shortages of critical drugs, particularly in the United States.
For critical insights on this market, request for methodology here- https://www.factmr.com/connectus/sample?flag=RM&rep_id=4681
Key Takeaways of Global Generic Injectables Market Study:
- Large-molecule injectables are projected to capture an impressive market share, tantamount to 3/5th of the overall generic injectables market. Burgeoning research and development in biosimilar products and anticipated patent expiry of blockbuster molecules are projected to leverage market share.
- By container, the prefilled syringes segment shall witness rapid expansion, registering an impressive CAGR of 14.1% during the forecast period. Dose accuracy and ease of administration are key growth drivers of this segment.
- Oncology specialists are anticipated to find maximum applicability of generic injectables. Rising number of cancer patients has augmented the need to use generic formulae to develop affordable and quality drugs. The segment is projected to account for around 30% of the overall generic injectables market.
Global Generic Injectables: Market Segmentation
Fact.MR has studied the global generic injectables market with detailed segmentation on the basis of product type, container type, application and key regions.
Product Type | Container Type | Application | Key Regions |
Large Molecule Injectables:mAb
Insulin Others |
Vials | Oncology | North America |
Small Molecule Injectables | Ampoules | Infectious diseases | Europe |
Premix | Cardiology | Asia Pacific | |
Prefilled syringes | Diabetes | Eastern Europe | |
Others | Immunology | Latin America | |
Others | Middle East & Africa (MEA) |
For in-depth competitive analysis, buy now – https://www.factmr.com/checkout/4681
Developing Pipeline Drugs to Remain Forte of Market Players
The global generic injectables market include, but are not limited to, players such as Pfizer, Inc., Novartis AG (Sandoz International GmbH), Baxter, Fresenius SE & Co., KGaA, Mylan N.V., Teva Pharmaceutical Industries Ltd., Hikma Pharmaceuticals PLC., Lupin Ltd., Sanofi and Biocon.
Read More Trending and Similar Reports from Fact.MR – https://www.globenewswire.com/en/news-release/2020/03/17/2001977/0/en/Demand-for-Hospital-Supplies-to-Heighten-with-Severing-Concerns-over-Hospital-Infections-Global-Market-Value-to-Surpass-US-21-Bn-by-2029-Fact-MR.html
About Us:
Market research and consulting agency with a difference! That’s why 80% of Fortune 1,000 companies trust us for making their most critical decisions. While our experienced consultants employ the latest technologies to extract hard-to-find insights, we believe our USP is the trust clients have on our expertise. Spanning a wide range – from automotive & industry 4.0 to healthcare & retail, our coverage is expansive, but we ensure even the most niche categories are analyzed. Our sales offices in United States and Dublin, Ireland. Headquarter based in Dubai, UAE. Reach out to us with your goals, and we’ll be an able research partner.
Contact:
US Sales Office:
11140 Rockville Pike
Suite 400
Rockville, MD 20852
United States
Tel: +1 (628) 251-1583
Corporate Headquarter:
Unit No: AU-01-H Gold Tower (AU),
Plot No: JLT-PH1-I3A,
Jumeirah Lakes Towers,
Dubai, United Arab Emirates
Email: sales@factmr.com
Visit Our Website: https://www.factmr.com
Editor Details
-
Company:
- MARKITWIRED Latest Market Reports
- Website: